Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
The extraordinary general meeting of AlzeCure Pharma AB approved the decision on the new issue of shares
April 25, 2024
-
AlzeCure publishes its interim report for January – March 2024
April 25, 2024
-
Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board
April 10, 2024